Oral cancer treatment: developments in chemotherapy and beyond (Q34998692)

5 August 2017

3 references

3 April 2019

14 September 2020

8 February 2021

Oral cancer treatment: developments in chemotherapy and beyond (English)

1 reference

lip and oral cavity carcinoma

5 August 2017

1 reference

3 April 2019

1 reference

1 reference

14 September 2020

1 reference

8 February 2021

1 reference

V J O'Neill

1

1 reference

5 August 2017

C J Twelves

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

British Journal of Cancer

5 August 2017

21 October 2002

3 references

3 April 2019

14 September 2020

8 February 2021

4 references

5 August 2017

3 April 2019

14 September 2020

8 February 2021

87

1 reference

5 August 2017

933-937

1 reference

5 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600591

5 August 2017

0 references

cites work

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

The EGFR as a target for anticancer therapy--focus on cetuximab

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

The oral fluoropyrimidines in cancer chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Oral chemotherapy: rationale and future directions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Patient preferences for oral versus intravenous palliative chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Patient compliance with oral chemotherapy as assessed by a novel electronic technique

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Characterization of human cytochrome P450 enzymes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

A study of quality of life in cancer patients receiving palliative chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

8 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600591

Protein kinases as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600591

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600591

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600591

Preclinical pharmacology of BMS-275183, an orally active taxane

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364332

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

26 October 2018

1 reference

12 December 2020

Oral efficacy and bioavailability of a novel taxane

1 reference

12 December 2020

Patient noncompliance with self-administered chemotherapy

1 reference

12 December 2020

An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600591

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference